Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas.
O'Sullivan Coyne G, Kummar S, Hu J, Ganjoo K, Chow WA, Do KT, Zlott J, Bruns A, Rubinstein L, Foster JC, Juwara L, Meehan R, Piekarz R, Streicher H, Sharon E, Takebe N, Voth AR, Bottaro D, Costello R, Wright JJ, Doroshow JH, Chen AP.
O'Sullivan Coyne G, et al. Among authors: do kt.
Clin Cancer Res. 2022 Jan 15;28(2):279-288. doi: 10.1158/1078-0432.CCR-21-2480. Epub 2021 Oct 29.
Clin Cancer Res. 2022.
PMID: 34716194
Free PMC article.